---
title: "Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282230447.md"
description: "Anbio Biotechnology reported strong FY25 results with sales of $8.65M, up from $8.19M in 2024. Net income surged to $6.4M, and earnings per share increased to 15 cents. The company is diversifying away from COVID products, generating 80.4% of IVD revenue from non-COVID sources. New product launches include a dry chemiluminescence immunoassay and a 15-minute PCR system. Anbio aims for long-term growth in the expanding IVD market, projected to reach $157.63 billion by 2030. Shares rose 21.30% to $26.94 in the past month."
datetime: "2026-04-09T16:46:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282230447.md)
  - [en](https://longbridge.com/en/news/282230447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282230447.md)
---

# Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

**Anbio Biotechnology (NASDAQ:NNNN)** reported full-year 2025 results on Tuesday, with sales rising to $8.65 million from $8.19 million in 2024.

Net income surged to $6.4 million, up from $2.37 million, while earnings from continuing operations jumped to 15 cents per share from 6 cents.

Gross margin expanded to 87.2% from 71.9%, driven by a higher-margin product mix and an outsourcing-led model, boosting profitability. Return on equity improved to roughly 21.1%.

## **Pivot Away From COVID Diagnostics**

Anbio, a medical technology and vitro diagnostics (IVD) company, has been actively diversifying away from COVID-19 diagnostics. In 2025, the company launched:

-   Dry chemiluminescence immunoassay (CLIA) – platform combining traditional CLIA with ease of use required for bedside testing.
-   15-minute PCR system – a molecular testing suite that provides definitive results for viruses like chikungunya in a fraction of the time required by standard PCR.

Anbio Biotechnology generated 80.4% of its commercial IVD revenue from non-COVID products in 2025. "Our strategy in 2025 was to build a more diversified and sustainable diagnostics business," said **Michael Lau**, CEO of Anbio Biotechnology. "By expanding into non-COVID IVD products, veterinary diagnostics and new testing platforms, we believe we are positioning the company for long-term growth and stronger profitability."

Anbio Biotechnology is transitioning to a broad multi-disease testing portfolio, including:

-   Launch of veterinary diagnostic tests for both home and clinical use
-   Introduction of dry chemistry product line to broaden diagnostic platform offerings
-   Exploration of advanced therapeutic areas targeting prevalent diseases

## **Large And Growing IVD Market**

With its Point-of-Care Testing (POCT) products, Anbio Biotechnology addresses a large and growth IVD market.

The global IVD market is projected to grow from an estimated $109.06 billion in 2025 to $157.63 billion in 2030. That represents a CAGR (compounded annual growth rate) of 7.6%.

**NNNN Price Action:** Shares of Anbio Biotechnology have risen by 21.30% to $26.94 over the past month.

_Image: Shutterstock_

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [NNNN.US](https://longbridge.com/en/quote/NNNN.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business](https://longbridge.com/en/news/286889480.md)
- [BUZZ-Dexcom to add two directors in deal with activist Elliott; shares up](https://longbridge.com/en/news/286465778.md)